Focused Ultrasound (FUS) is an emerging non-invasive therapeutic technology that uses precisely focused acoustic energy to treat neurological disorders. Unlike traditional surgical approaches, FUS allows clinicians to target deep brain structures without craniotomy or radiation. The technology has evolved from a single application (essential tremor) to a versatile platform with nearly 30 identified mechanisms of action, making it one of the most promising frontiers in neurodegenerative disease treatment.
FUS offers several distinct therapeutic modalities that can be tailored to specific neurological conditions:
- Low-Intensity FUS (LIFU): Temporarily opens the blood-brain barrier (BBB) to enhance drug delivery
- High-Intensity Focused Ultrasound (HIFU): Thermally ablates targeted tissue
- Sonodynamic Therapy (SDT): Activates therapeutic agents through acoustic activation
Focused ultrasound operates by concentrating multiple ultrasound waves onto a precise focal point within the brain. The intersection of these beams creates a region of focused acoustic energy while sparing surrounding tissue. This precision allows treatments to target structures as small as 1×1.5 mm or as large as 10×16 mm in diameter.
The biological effects of ultrasound are determined primarily by two key parameters:
- Mechanical Index (MI): Relates to cavitation effects
- Thermal Index (TI): Relates to heating effects
| Intensity Level |
Primary Effect |
Clinical Application |
| Low (0.1-1 W/cm²) |
Cavitation, BBB opening |
Drug delivery |
| Medium (1-10 W/cm²) |
Neuromodulation |
Targeted stimulation |
| High (>10 W/cm²) |
Thermal ablation |
Tumor/volume ablation |
Modern FUS systems integrate with advanced imaging modalities:
- MR-guided FUS (MRgFUS): Real-time temperature mapping and anatomical visualization
- CT-guided FUS: Bone compensation algorithms for skull trans skull treatment
- Transcranial Doppler: Blood flow monitoring during treatment
The blood-brain barrier (BBB) presents a formidable obstacle to CNS drug delivery, preventing approximately 98% of small molecule drugs and virtually all large molecule therapeutics (proteins, antibodies, gene therapies) from reaching the brain. Low-intensity FUS combined with circulating microbubbles can induce temporary, reversible opening of the BBB through mechanical effects.
When focused ultrasound is applied to the brain vasculature in the presence of circulating microbubbles, the acoustic pressure causes the bubbles to oscillate (stable cavitation) or collapse (inertial cavitation). These mechanical effects produce:
- Tight junction modulation: Mechanical stress temporarily disrupts endothelial tight junctions, increasing paracellular permeability
- Transcytosis enhancement: Triggers increased vesicular transport across endothelial cells
- Carrier-mediated transport: Upregulates transport mechanisms for therapeutic agents
¶ Safety and Reversibility
BBB opening is designed to be temporary and reversible:
- Duration: The BBB typically reopens within 24-48 hours post-treatment
- Safety margins: Real-time cavitation monitoring ensures parameters remain within safe limits
- No permanent damage: Studies show complete recovery of tight junction integrity
flowchart TD
classDef inputs fill:#e1f5fe,stroke:#333
classDef intermediates fill:#fff3e0,stroke:#333
classDef decisions fill:#fff9c4,stroke:#333
classDef outcomes fill:#c8e6c9,stroke:#333
classDef pathology fill:#ffcdd2,stroke:#333
classDef therapeutic fill:#f3e5f5,stroke:#333
subgraph APPLICATION["Focused Ultrasound Application"]
A["Focused Ultrasound<br/>Application"]:::inputs
end
B{"Intensity Level"}:::decisions
A --> B
B -->|"Low Intensity"| C["Microbubble<br/>Circulation"]:::intermediates
B -->|"High Intensity"| D["Thermal<br/>Ablation"]:::pathology
C --> E["<b>Cavitation Effect</b><br/>Mechanical<br/>Oscillation"]:::intermediates
E --> F["<b>BBB Opening</b><br/>Tight Junction<br/>Modulation"]:::therapeutic
F --> G["<b>Therapeutic Agent</b><br/>Delivery"]:::therapeutic
G --> H{"Target"}:::decisions
H -->|"AD"| I["Anti-Aβ Antibodies<br/>Lecanemab / Donanemab"]:::outcomes
H -->|"PD"| J["Neurotrophic Factors<br/>GDNF / BDNF"]:::outcomes
H -->|"Gene Therapy"| K["AAV Vectors<br/>siRNA"]:::therapeutic
I --> L["<b>Amyloid Clearance</b><br/>Plaque Reduction"]:::outcomes
J --> M["<b>Neuroprotection</b><br/>Dopaminergic<br/>Neuron Rescue"]:::outcomes
K --> N["<b>Gene Expression</b><br/>Targeted<br/>Transduction"]:::therapeutic
L --> O["<b>Alzheimer's Disease</b><br/>Cognitive<br/>Improvement"]:::outcomes
M --> P["<b>Parkinson's Disease</b><br/>Motor Function<br/>Preservation"]:::outcomes
N --> Q["<b>Modified Disease</b><br/>Process<br/>Slowing"]:::outcomes
D --> R["<b>Thalamotomy</b><br/>Tremor<br/>Suppression"]:::pathology
D --> S["<b>GPi / STN Ablation</b><br/>Dyskinesia<br/>Reduction"]:::pathology
R --> T["Essential Tremor<br/>PD Tremor"]:::outcomes
S --> U["PD Motor<br/>Symptoms"]:::outcomes
click A "/mechanisms/focused-ultrasound-neurodegeneration" "Focused Ultrasound"
click F "/mechanisms/blood-brain-barrier" "BBB Mechanism"
click I "/therapeutics/lecanemab" "Lecanemab"
click I "/therapeutics/donanemab" "Donanemab"
click J "/therapeutics/gdnf-gene-therapy" "GDNF Therapy"
click J "/therapeutics/bdnf-neurotrophin" "BDNF Therapy"
click K "/therapeutics/aav-gene-therapy-neurodegeneration" "AAV Gene Therapy"
click O "/diseases/alzheimers-disease" "Alzheimer's Disease"
click P "/diseases/parkinsons-disease" "Parkinson's Disease"
click R "/mechanisms/focused-ultrasound-neurodegeneration#surgical-applications" "Thalamotomy"
click S "/mechanisms/focused-ultrasound-neurodegeneration#surgical-applications" "GPi/STN Ablation"
LIFU-BBB opening enables delivery of:
- Monoclonal antibodies: Aducanumab, Lecanemab, Donanemab
- Gene therapies: AAV vectors, siRNA, antisense oligonucleotides
- Small molecules: Antioxidants, neuroprotective compounds, BACE inhibitors
- Nanoparticles: Targeted drug carriers designed for CNS delivery
HIFU delivers concentrated acoustic energy that is absorbed by tissue, generating localized heating. Temperatures of 55-80°C are achieved at the focal point, causing immediate and irreversible coagulation necrosis while the surrounding tissue remains unharmed.
The precision of HIFU ablation depends on:
- Acoustic power: Higher power creates larger lesions
- Exposure duration: Longer treatments create larger ablations
- Focus size: Smaller foci enable more precise targeting
In 2016, the FDA approved Insightec's Exablate Neuro device for treating essential tremor through thalamotomy—targeting the ventral intermediate nucleus (VIM) of the thalamus.
In December 2018, the FDA approved Exablate Neuro for tremor-dominant Parkinson's disease, specifically targeting the thalamus. This was expanded in 2021 to include patients with advanced PD suffering from mobility, rigidity, or dyskinesia symptoms.
| Target |
Indication |
Effect |
| Vim thalamus |
Tremor |
Tremor suppression |
| GPi |
PD dyskinesias |
Motor improvement |
| STN |
PD motor symptoms |
Reduced medication |
| Subthalamic nucleus |
PD |
Symptom control |
Sonodynamic therapy combines low-intensity ultrasound with systemically administered sonosensitizers—compounds that become cytotoxic when activated by acoustic energy. Unlike photodynamic therapy (which requires light), SDT can penetrate deep into brain tissue.
- Systemic administration: Sonosensitizer drugs are delivered intravenously
- Accumulation: The agent accumulates in target tissue (tumors, pathological protein aggregates)
- Ultrasound activation: Focused ultrasound activates the sensitizer
- Reactive oxygen species (ROS) generation: Creates cytotoxic singlet oxygen and other ROS
- Targeted cell death: Selective destruction of activated cells
SDT is being investigated for:
- Alpha-synuclein clearance in Parkinson's disease
- Amyloid plaque reduction in Alzheimer's disease
- Glioblastoma treatment (actively in clinical trials)
FUS-enhanced delivery enables anti-amyloid therapeutics to reach the brain at therapeutic concentrations. Studies in AD mouse models have shown that FUS-enhanced delivery of anti-Aβ antibodies reduces amyloid plaque burden more effectively than systemic administration alone.
The first Alzheimer's trial using FUS to temporarily disrupt the BBB began in 2017 at Sunnybrook Research Institute in Toronto, Canada. Multiple Phase I/II trials are now underway to assess:
- Safety and tolerability of repeated BBB opening
- Biomarker changes (CSF Aβ, tau, neurofilament light chain)
- Cognitive outcomes
- Sunnybrook Research Institute (Toronto): Pioneered first-in-human FUS-BBB opening
- University of Virginia: Developed next-generation FUS technology
- Stanford University: Clinical translation studies
FUS has shown particular promise in PD, with multiple FDA approvals for tremor treatment. The FDA expanded approval in 2021 to include treatment of patients with advanced PD suffering from mobility, rigidity, or dyskinesia symptoms.
In 2022, researchers in Spain used FUS to open the BBB in people with Parkinson's dementia, marking the first application for this specific indication.
FUS enables delivery of:
- GDNF (Glial Cell Line-Derived Neurotrophic Factor)
- BDNF (Brain-Derived Neurotrophic Factor)
- Gene therapy vectors encoding aromatic L-amino acid decarboxylase (AADC)
- CMS began covering FUS for PD in 2020
- Multiple trials ongoing for motor symptoms and dementia
FUS applications in ALS focus on:
- Delivery of neurotrophic factors to protect motor neurons
- Anti-SOD1 oligonucleotide delivery for genetic ALS
- Enhanced delivery of immunomodulatory agents
Research is exploring FUS-enhanced delivery of:
- Tau-targeting antibodies
- Gene silencing constructs
- Anti-inflammatory agents
FUS may enable:
- Delivery of gene silencing constructs targeting mutant huntingtin
- Enhanced delivery of neuroprotective compounds
- Targeted ablation of pathological circuits
¶ Clinical Trial Landscape
¶ Active and Completed Trials
| Trial ID |
Condition |
Phase |
Intervention |
Status |
| NCT02986932 |
AD |
Phase I |
FUS + Donepezil |
Completed |
| NCT04571632 |
PD |
Phase I/II |
FUS Thalamotomy |
Recruiting |
| NCT03344787 |
Glioblastoma |
Phase I |
FUS + Pembrolizumab |
Active |
| NCT04118764 |
Breast Cancer Brain Mets |
Phase I |
FUS + Docetaxel |
Recruiting |
- Insightec: FDA-approved Exablate Neuro device
- Carthera: SonoCloud device for repeated BBB opening
- Cerebral Therapeutics: Implantable FUS device
Clinical trials have established a favorable safety profile:
- Common: Headache, mild dizziness (typically transient)
- Less common: Transient numbness, balance disturbances
- Rare: Microhemorrhage (extremely rare with proper monitoring)
- Metallic implants in the treatment path
- Uncontrolled coagulopathy
- Active infection
- Certain cardiac conditions
Studies with up to 5-year follow-up show no increased risk of:
- Cognitive decline
- New neurological deficits
- Brain atrophy
| Parameter |
Typical Range |
Notes |
| Frequency |
0.2-2 MHz |
Lower frequencies favor cavitation |
| Peak negative pressure |
0.3-1.5 MPa |
Above threshold induces cavitation |
| Pulse duration |
1-10 ms |
Shorter pulses reduce heating |
| Pulse repetition frequency |
1-10 Hz |
Determines total exposure |
| Total treatment time |
30-120 seconds |
Per target region |
Modern systems incorporate:
- Passive cavitation detection: Monitors bubble activity
- MR thermometry: Tracks temperature in real-time
- Acoustic feedback: Ensures safe energy delivery
- Blood-CSF barrier targeting: Focusing on the choroid plexus for CSF-mediated delivery
- Targeted vascular targeting: Using vascular neural interfaces for localized delivery
- Closed-loop systems: Real-time feedback control based on biomarker monitoring
- Personalized parameters: Using MRI-guided treatment planning for individual patients
FUS can be combined with:
- Immunotherapy: FUS-enhanced delivery of antibodies combined with immunomodulators
- Gene therapy: AAV delivery enhanced by FUS for more efficient CNS transduction
- Cell therapy: FUS-enhanced delivery of stem cells
- Photodynamic therapy: FUS can enhance delivery of photosensitizers
Recent advances in focused ultrasound for neurodegeneration: